Data mining Inhaled corticosteroid Beclometasone dipropionate (bdp) equivalent dose from routine primary care records

C. Newby (London, United Kingdom), D. Marke (LondonLondon, United Kingdom), S. Mckibben (LLonodnondonLondon, United Kingdom), C. Griffiths (LondonLLonodnondonLondon, United Kingdom)

Source: International Congress 2018 – Primary care management of COPD
Session: Primary care management of COPD
Session type: Thematic Poster
Number: 918
Disease area: Airway diseases

Congress or journal article abstract

Abstract

Introduction

Routine primary care data contains prescription data for treatments for respiratory diseases these include trade names for corticosteroid drugs, both on their own and combined with Long Acting Beta Agonists (LABA).  This data usually contains the treatment and dose in one field and the direction of treatment in another.  There is a need to obtain usable analysable data for standardised corticosteroid dose from routine data.

Aim

To obtain and test text matching algorithms that can mine bdp equivalent corticosteroid dose from routine primary care data.     

Methods

We created string matching algorithms in R language to determine which inhaled corticosteroid a patient was on.  We then mined the dose from the text field containing the description of the inhaled corticosteroid.  We further used string matching algorithms to determine how many times the patient took their inhaler in a day, i.e. “two puffs, twice a day”.    

Results

The algorithms worked on all fields without missing data. For evaluation the data will be compared to 100 new records using the reference standard of a trained Asthma professional looking through the records and obtaining the bdp using written down rules.  Thus the predictive sensitivity and specificity will be calculated for the algorithms.

Conclusions

It is possible to obtain bdp equivalent from routine primary care using string matching algorithms to obtain trade name of drug, dose of drug and number of puffs per day to obtain total dosage per day and converting to bdp equivalent.



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Newby (London, United Kingdom), D. Marke (LondonLondon, United Kingdom), S. Mckibben (LLonodnondonLondon, United Kingdom), C. Griffiths (LondonLLonodnondonLondon, United Kingdom). Data mining Inhaled corticosteroid Beclometasone dipropionate (bdp) equivalent dose from routine primary care records. 918

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS)
Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD
Year: 2015

Comparative effectiveness analysis: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate vs fluticasone propionate with spacer in children
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013


Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 471s
Year: 2002

Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013


Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013


Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Dose comparability of fluticasone (F) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma using dose step-down study design
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021



QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Identification of asthma level of control using administrative data of short-acting beta-agonist inhalers purchase
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016

High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010

Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Pharmacokinetic and pharmacodynamic evaluation after administration of beclomethasone dipropionate and formoterol fumarate as fixed or free metered-dose inhaler combination in adolescent asthma
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001